pyrroles has been researched along with Body Weight in 116 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (9.48) | 18.7374 |
| 1990's | 10 (8.62) | 18.2507 |
| 2000's | 36 (31.03) | 29.6817 |
| 2010's | 54 (46.55) | 24.3611 |
| 2020's | 5 (4.31) | 2.80 |
| Authors | Studies |
|---|---|
| Gotoda, T; Horii, T; Ichijima, R; Ikehara, H; Kusano, C; Ogura, K; Sugita, T; Suzuki, S; Takano, C | 1 |
| Li, M; Li, X; Liu, Z; Wang, Q; Wang, S; Xie, K; Yu, T | 1 |
| Jiang, L; Li, M; Li, X; Liu, Z; Wang, Q; Xie, K; Yu, T | 1 |
| Gelderblom, H; Healey, JH; Kang, J; Knebel, W; Shuster, D; Stacchiotti, S; Tap, WD; van de Sande, M; Wagner, AJ; Yin, O; Zahir, H | 1 |
| Bousquet, P; Fellmann, L; Monassier, L; Niederhoffer, N; Regnard, P; Weiss, M | 1 |
| Gupta, P; Hutmacher, MM; Ito, K; Krishnaswami, S; Mebus, C; Papp, K; Rottinghaus, ST; Tan, H; Valdez, H; Wolk, R | 1 |
| Del Zotto, H; Flores, LE; Gagliardino, JJ; Maiztegui, B; Román, CL | 1 |
| Andersen, MA; Badolo, L; Christensen, KV; Jeggo, R; Jensen, PH; Larsen, S; Smith, GP; Sotty, F; Thougaard, A; Wegener, KM | 1 |
| Dickinson, NJ; Harper, J; Howard, P; Mao, S; Masterson, L; Pechenov, S; RiosDoria, J; Subramony, JA; Tyagi, P; Wetzel, L; Yo, K | 1 |
| Bousquet, P; Gomes, F; Gonçalves-de-Albuquerque, C; Machado, MV; Nascimento, AR; Tibiriçá, E | 1 |
| Aubertin, G; Benameur, D; Bousquet, P; Choquet, P; Dali-Youcef, N; Greney, H; Monassier, L; Niederhoffer, N; Pons, F; Sigrist, S; Traversi, F; Weiss, M | 1 |
| Alves, VS; Costa, R; Dias, FC; Figueiredo, CP; Matias, DO; Miranda, ALP; Passos, GF | 1 |
| Morton, D; Nambiar, PR | 1 |
| Alencar, NM; Benevides, NM; Goes, P; Lima, V; Melo, IM; Ribeiro, RA; Silva, LM | 1 |
| Prado, CM | 1 |
| Bousquet, P; Chetrite, G; Fellmann, L; Fève, B; Gasparik, V; Gigou, L; Greney, H; Julien, C; Lacolley, P; Max, JP; Muscat, A; Niederhoffer, N; Oréa, V; Pizard, A; Regnault, V | 1 |
| Dervan, PB; Hamilton, SR; Li, BC; Meier, JL; Nickols, NG; Szablowski, JO; Wang, CM; Yang, F | 1 |
| Marrion, NV; Robertson, JD; Robinson, ES; Stuart, SA | 1 |
| Khoramjouy, M; Malekinejad, H; Mehrabi, M; Rezaei-Golmisheh, A | 1 |
| Abreu, GR; Andrade, TU; Bissoli, NS; Caliman, IF; Dalpiaz, PL; Figueiredo, SG; Gusmão, LN; Lamas, AZ; Medeiros, AR | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Dang, XM; Ma, AQ; Yang, L; Zhu, B | 1 |
| Ceron, CS; Gerlach, RF; Guimarães, DA; Pinheiro, LC; Rizzi, E; Tanus-Santos, JE | 1 |
| Emoto, N; Hirata, K; Nakayama, K; Suzuki, Y; Van Hung, T; Vignon-Zellweger, N; Yagi, K | 1 |
| Du, Y; Gao, J; Hu, R; Lu, M; Wang, Y; Wei, W; Zhang, S; Zhou, Q; Zhu, H; Zuo, L | 1 |
| Fu, G; Gong, X; Ma, Y; Ruan, Y; Wu, S | 1 |
| Guo, Y; Shao, X; Xie, K; Yin, H; Zeng, T; Zhang, C; Zhao, X | 1 |
| Aslam, M; Bhattacharya, SK; Galav, V; Jafri, AA; Madhu, SV | 1 |
| Abdelbary, A; Hamza, M; Unis, A | 1 |
| Chang, CY; Chang, KC; Chang, RW; Chen, YS; Ko, WJ; Ko, YH; Tsai, PR; Wang, CH; Wang, SS; Young, TH | 1 |
| Barter, PJ; DeMicco, DA; Messig, M; Ong, KL; Rye, KA; Waters, DD | 1 |
| Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y | 1 |
| Alexandre, J; Behouche, A; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Huillard, O; Loriot, MA; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
| Beijnen, JH; de Wit, D; Huitema, AD; Kloth, JS; Mathijssen, RH; Schellens, JH; Steeghs, N; van Erp, NP; van Hasselt, JG; Yu, H | 1 |
| Bento, CF; Fernandes, R; Matafome, P; Pereira, P; Seiça, RM; Sena, CM | 1 |
| Bobilev, A; Branch, A; Cai, H; Negrao, NW; Shen, P | 1 |
| Balansky, R; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; La Maestra, S; Micale, RT; Nikolov, M; Steele, VE | 1 |
| Holmes, GL; Isaev, D; Isaeva, E; Lunko, O; Lushnikova, I; Maximyuk, O; Romanov, A; Skibo, GG; Tian, C; Zapukhliak, O | 1 |
| Alpini, G; Kumar, N; Meng, F; Mishra, J; Verma, RK | 1 |
| Fan, C; Lu, P; Qin, H; Wang, Y; Xue, X; Yuan, X; Zhang, Q | 1 |
| Fumagalli, E; Khosravan, R; Motzer, RJ; Rini, BI | 1 |
| Abdel-Aziz, AK; Helwa, R; Mantawy, EM; Said, RS | 1 |
| Basilico, N; Brun, R; Casagrande, M; Parapini, S; Sparatore, A; Sparatore, F; Taramelli, D; Wittlin, S | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 1 |
| Borsini, F; Caprioli, A; Carminati, P; Coccurello, R; Conti, R; Ghirardi, O; Moles, A | 1 |
| Dhaliwal, S; Galloway, S; Jian, L; Johnsen, R; Mamo, JC; Pallebage-Gamarallage, MM | 1 |
| Burnett, K; Chang, WY; Chen, Y; Griffiths, KN; Hogue, A; López, FJ; Mais, DE; Marschke, K; Meglasson, MD; Pedram, B; Shen, Y; Vajda, EG; van Oeveren, A; Zhi, L | 1 |
| Duranti, A; LoVerme, J; Mor, M; Piomelli, D; Rivara, S; Spadoni, G; Stella, N; Tarzia, G; Tontini, A; Xu, C | 1 |
| Chen, IJ; Hsieh, SL; Kwan, AL; Lin, HL; Shen, KP; Wu, BN | 1 |
| Boyle, A; Connelly, KA; Gilbert, RE; Kelly, D; Kompa, A; Krum, H; Martin, JH; Zhang, Y | 1 |
| Berga, SL; Kaplan, JR; Michopoulos, V; Wilson, ME | 1 |
| Arany, EJ; Hill, DJ; Marchand, KC | 1 |
| Suddek, GM | 1 |
| Kalonia, H; Kumar, A; Kumar, P | 2 |
| Chen, P; Duan, S; Gan, Y; Jiang, LZ; Li, GY; Wu, SJ; Zhang, J; Zhang, Y; Zhao, SP | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Matsuura, T; Miyazaki, K; Morimoto, N; Nagai, M; Ohta, Y; Panin, VL | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Andersson, KE; Eussen, SR; Garssen, J; Hellstrand, P; Klungel, OH; Oste, R; Rompelberg, CJ; van Kranen, H | 1 |
| Morimoto, J; Otsuki, Y; Shibata, MA; Tanaka, Y | 1 |
| Andalib, S; Biabani, S; Doustar, Y; Garjani, A; Maleki-Dizaji, N; Soraya, H | 1 |
| Bink, DI; Breuer, ME; Douma, TN; Hendriksen, H; Meulendijks, D; Olivier, B; Oosting, RS; Westphal, KG | 1 |
| Danser, AH; de Krijger, RR; Eechoute, K; Kappers, MH; Leijten, F; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH; van Esch, JH; Visser, TJ | 1 |
| Bowman, CJ; Cappon, GD; Coburn, AM; Patyna, S; Stedman, DB | 1 |
| Dervan, PB; Hargrove, AE; Raskatov, JA; So, AY | 1 |
| Abraham, WT; Ghali, JK; Orlandi, C | 1 |
| Fellström, B; Ferraz, N; Mihranyan, A; Nyholm, L; Pradhan, S; Strømme, M | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Redgrave, TG; Watts, GF | 1 |
| Engel, JB; Halmos, G; Hammann, B; Keller, G; Nagy, A; Schally, AV | 1 |
| Abe, K; Deguchi, K; Hayashi, T; Nagano, I; Nagotani, S; Sato, K; Shoji, M; Zhang, W | 1 |
| Fantus, IG; Lewis, GF; Stavar, L; Szeto, L; Uffelman, K; Wang, CH; Wong, V | 1 |
| Deng, P; Hong, SC; Wu, J; Wu, ZH; Zhao, SP | 1 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Donkin, SS; Elkin, RG; Hengstschläger-Ottnad, E; Schneider, WJ; Zhong, Y | 1 |
| Balaraman, R; Bothara, SB; Majithiya, JB; Trivedi, CJ | 1 |
| Huang, TG; Mondo, CK; Su, JZ; Yang, WS | 2 |
| Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M | 1 |
| Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Podlogar, B; Smith, RA; Taing, C; Tomlinson, S; Tritto, T; Zhang, Z | 1 |
| Chen, XQ; Dong, J; Du, JZ; Fan, JM; Niu, CY | 1 |
| Gorbas', IM; Iakimishina, LI; Kaĭdashev, IP; Petrushov, AV; Rasin, AM; Rasin, MS; Smirnova, IP; Vasil'ev, VN | 1 |
| Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M | 1 |
| Parle, M; Singh, N | 1 |
| Birnbaum, Y; Huang, MH; Hughes, MG; Lin, Y; Lui, CY; Manickavasagam, S; McAdoo, DJ; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Bauersachs, J; Brandt, M; Closs, E; Daiber, A; Ertl, G; Förstermann, U; Münzel, T; Oelze, M; Thum, T; Wenzel, P; Xu, J; Zou, MH | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Ballerini, C; Bellucci, A; Biagioli, T; Biamonte, F; Casamenti, F; Grossi, C; Luccarini, I; Massacesi, L; Rosi, MC | 1 |
| Bujo, H; Hanaoka, H; Kodama, T; Mikami, K; Miyashita, Y; Nishikawa, T; Saito, Y; Shinomiya, M; Tada, N; Yokote, K | 1 |
| Lacher, JW; Miller, FC; Schorr, WJ | 1 |
| Anderson, JA; Dostal, LA; Schardein, JL | 1 |
| Albrecht, W; Algate, DR; Atterson, PR; Augustin, J; Elsässer, R; Guserle, R; Laufer, S; Munt, PL; Tries, S | 1 |
| Baeyens, JM; Barrios, M; Robles, LI | 1 |
| Abe, I; Fujii, K; Fujishima, M; Nagao, T; Ohya, Y; Setoguchi, M | 1 |
| Chu, CY; Hsu, JD; Lin, YL; Tseng, TH; Wang, CJ | 1 |
| Groot, K; Koppan, M; Kovacs, M; Nagy, A; Schally, AV | 1 |
| Anderson, JA; Black, A; Colgin, J; Craft, WR; Henck, JW | 1 |
| Bornstein, SR; Chrousos, GP; Igel, M; Joost, HG; Lewis, DB; Mitsiades, N; Rice, KC; Richman, SJ; Torpy, DJ; Tsokos, M; Webster, EL | 1 |
| Barnaby, R; Bottacini, M; Hoke, JF; Iavarone, L; Preston, GC | 1 |
| Halmos, G; Kiaris, H; Nagy, A; Schally, AV; Sun, B; Szepeshazi, K | 1 |
| Rauscher, FM; Sanders, RA; Watkins, JB | 1 |
| Abman, SH; Gebb, S; Hirth, KP; Jakkula, M; Le Cras, TD; Tuder, RM; Voelkel, NF | 1 |
| Hartmann, B; Holst, JJ; Kissow, H; Orskov, C; Poulsen, SS; Ropke, C; Thulesen, J; Thulesen, S | 1 |
| Beinlich, CJ; Ichihara, K; Morgan, HE; Satoh, K; Shirota, F; Tsunajima, T | 1 |
| Belogi, L; Mezzadri, CM; Tubaro, E | 1 |
| Boquist, S; Danell-Toverud, K; Hamsten, A; Karpe, F | 1 |
| Dominick, MA; McGuire, EJ; Sigler, RE | 1 |
| Braun, RC; Dickinson, JO | 1 |
| Briggs, RG; DeCaprio, AP; Jackowski, SJ; Kim, JC | 1 |
| Boekelheide, K; Eveleth, J | 1 |
| Gambetti, P; Medori, R; Sayre, LM; Shearson, CM; Wongmongkolrit, T | 1 |
| Doremus, HM; Dunsford, HA; Jaffe, JJ; Meymarian, E | 1 |
| Allen, JR; Hsu, IC | 1 |
| Plestina, R; Stoner, HB | 1 |
| Iizuka, Y; Tanaka, K | 1 |
| Brown, H; Deleña, S | 1 |
| Cabadaj, S; Kolousek, J | 1 |
2 review(s) available for pyrroles and Body Weight
| Article | Year |
|---|---|
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Weight; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Racial Groups; Sex Factors; Sunitinib | 2016 |
10 trial(s) available for pyrroles and Body Weight
| Article | Year |
|---|---|
Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Area Under Curve; Asian People; Bacterial Proteins; Body Weight; Creatinine; Female; Giant Cell Tumor of Tendon Sheath; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Pyrroles; Racial Groups; Sex Factors; Sociodemographic Factors; Tumor Burden; Young Adult | 2021 |
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Topics: Administration, Oral; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Models, Biological; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).
Topics: Atorvastatin; Body Weight; Coronary Artery Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Style; Male; Middle Aged; Pyrroles; Risk Factors; Time Factors; Weight Loss | 2014 |
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Topics: Aged; Angiogenesis Inhibitors; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Body Weight; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrroles; Receptors, Steroid; Sunitinib; Treatment Outcome | 2015 |
The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzamides; Body Weight; Double-Blind Method; Female; Health Status Indicators; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Outpatients; Pyrroles; Statistics as Topic; Stroke Volume; Ventricular Function, Left; Young Adult | 2012 |
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Topics: Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Fasting; Fatty Acids, Nonesterified; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Obesity; Placebos; Pyrroles | 2002 |
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Ghrelin; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Peptide Hormones; Pyrroles; Resistin | 2007 |
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis preventi
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Body Mass Index; Body Weight; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Waist Circumference | 2008 |
First time in human for GV196771: interspecies scaling applied on dose selection.
Topics: Administration, Oral; Animals; Area Under Curve; Body Weight; Brain; Dogs; Excitatory Amino Acid Antagonists; Glycine Agents; Humans; Indoles; Injections, Intravenous; Macaca fascicularis; Male; Metabolic Clearance Rate; Organ Size; Pyrroles; Rats; Species Specificity | 1999 |
Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipids; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Postprandial Period; Pyrroles; Sweden; Time Factors; Treatment Outcome; Triglycerides | 2002 |
104 other study(ies) available for pyrroles and Body Weight
| Article | Year |
|---|---|
Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.
Topics: Amoxicillin; Anti-Bacterial Agents; Body Weight; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Diallyl sulfide-induced attenuation of n-hexane-induced peripheral nerve impairment is associated with metabolic inhibition of n-hexane.
Topics: Allyl Compounds; Animals; Body Weight; Hair; Hexanes; Hexanones; Male; Neuroprotective Agents; Neurotoxicity Syndromes; Pyrroles; Rats, Wistar; Sciatic Nerve; Sulfides | 2020 |
No-observed-adverse-effect level of hair pyrrole adducts in chronic n-hexane intoxication in rats.
Topics: Animals; Behavior, Animal; Biomarkers; Body Weight; Gait; Hair; Hexanes; Male; No-Observed-Adverse-Effect Level; Pyrroles; Rats, Wistar; Rotarod Performance Test | 2020 |
Protective effects of the imidazoline-like drug lnp599 in a marmoset model of obesity-induced metabolic disorders.
Topics: Aniline Compounds; Animals; Body Weight; Callithrix; Disease Models, Animal; Imidazolines; Male; Metabolic Diseases; Obesity; Protective Agents; Pyrroles | 2021 |
INGAP-PP effects on β-cell mass and function are related to its positive effect on islet angiogenesis and VEGFA production.
Topics: Animals; Apoptosis; Body Weight; Cell Size; Cytokines; DNA; Feeding Behavior; Glucose; Glucose Tolerance Test; Indoles; Insulin; Insulin-Secreting Cells; Integrin beta1; Male; Neovascularization, Physiologic; Peptide Fragments; Pyrroles; Rats, Wistar; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats.
Topics: Animals; Body Weight; Enzyme Inhibitors; Female; Kidney; Kidney Function Tests; Kidney Tubules, Proximal; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lung; Morpholines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley | 2018 |
Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach.
Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Body Weight; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Humans; Inhibitory Concentration 50; Injections, Intravenous; Mice; Nanoparticles; Neoplasms; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrroles; Xenograft Model Antitumor Assays | 2019 |
I
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diet, High-Fat; Disease Models, Animal; Heart Rate; Imidazoline Receptors; Lipids; Male; Metabolic Syndrome; Microcirculation; Pyrroles; Rats; Rats, Wistar; Sympathetic Nervous System | 2019 |
Effects of imidazoline-like drugs on liver and adipose tissues, and their role in preventing obesity and associated cardio-metabolic disorders.
Topics: Adipose Tissue; Aniline Compounds; Animals; Body Weight; Eating; Hep G2 Cells; Humans; Imidazolines; Liver; Male; Metabolic Diseases; Obesity; Pyrroles; Rats; Rats, Zucker | 2019 |
The selective TRPV4 channel antagonist HC-067047 attenuates mechanical allodynia in diabetic mice.
Topics: Animals; Body Temperature; Body Weight; Diabetic Neuropathies; Ganglia, Spinal; Gene Expression Regulation; Hyperalgesia; Locomotion; Male; Mice; Morpholines; Psychomotor Performance; Pyrroles; Sciatic Nerve; TRPV Cation Channels | 2019 |
The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Topics: Animals; Body Weight; Carcinogenicity Tests; Cell Proliferation; Female; Genes, ras; Indoles; Male; Mice; Mice, Transgenic; Models, Animal; Neoplasms, Experimental; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib | 2013 |
Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats.
Topics: Acid Phosphatase; Alanine Transaminase; Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Animals; Aspartate Aminotransferases; Atorvastatin; Body Weight; Bone Density Conservation Agents; Dental Cementum; Gingiva; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Parenteral; Injections, Subcutaneous; Isoenzymes; Leukocyte Disorders; Leukocytes; Leukocytosis; Male; Monocytes; Neutrophils; Peroxidase; Pyrroles; Rats, Wistar; Root Resorption; Tartrate-Resistant Acid Phosphatase | 2014 |
A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats.
Topics: 3T3-L1 Cells; Adiponectin; Aniline Compounds; Animals; Blood Pressure; Body Weight; Glucose Intolerance; Glucose Tolerance Test; Imidazoline Receptors; Insulin Resistance; Kidney; Lipids; Male; Metabolic Syndrome; Mice; Pyrroles; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Surface Plasmon Resonance; Sympathetic Nervous System | 2013 |
Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit.
Topics: Animals; Antineoplastic Agents; Biological Transport; Body Weight; Dose-Response Relationship, Drug; Drug Stability; Humans; Imidazoles; Liver; Male; Mice; Microsomes, Liver; Nylons; Pyrroles; Structure-Activity Relationship; Toxicity Tests; Xenograft Model Antitumor Assays | 2013 |
Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory.
Topics: Animals; Atorvastatin; Body Weight; Cholesterol; Cognition; Discrimination, Psychological; Heptanoic Acids; Male; Memory; Pravastatin; Pyrroles; Rats; Reversal Learning; Time Factors | 2013 |
Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors.
Topics: Anilides; Animals; Atorvastatin; Body Weight; Heptanoic Acids; Herbicides; Hydroxyproline; Lung; Male; Organ Size; Paraquat; Pioglitazone; PPAR gamma; Protective Agents; Pulmonary Fibrosis; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Thiazolidinediones; Transforming Growth Factor beta1 | 2013 |
Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats.
Topics: Acetylcholine; Animals; Atorvastatin; Biological Factors; Blotting, Western; Body Weight; Cholesterol; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Endothelium, Vascular; Female; Heptanoic Acids; Mesenteric Arteries; NADPH Oxidases; Nitric Oxide Synthase; Organ Size; Ovariectomy; Oxidative Stress; Prostaglandins; Pyrroles; Rats, Wistar; Reactive Oxygen Species; Uterus; Vasodilation | 2013 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.
Topics: Animals; Atorvastatin; Bleomycin; Body Weight; Collagen; Connective Tissue Growth Factor; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Male; Malondialdehyde; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Pulmonary Fibrosis; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction | 2013 |
Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension.
Topics: Animals; Aorta; Atorvastatin; Blood Pressure; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hypertension, Renovascular; Male; Nitric Oxide; Piperazines; Purines; Pyrroles; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2013 |
Inhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: potential roles of interleukin-6 and endothelin.
Topics: Animals; Biomarkers; Body Weight; Cell Hypoxia; Cell Line; Disease Models, Animal; Endothelial Cells; Endothelin-1; Heart Rate; Humans; Hypertension, Pulmonary; Indoles; Inflammation; Interleukin-6; Lung; Male; Mice; Pulmonary Artery; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Up-Regulation | 2014 |
Atorvastatin inhibits hyperglycemia-induced expression of osteopontin in the diabetic rat kidney via the p38 MAPK pathway.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Diabetic Nephropathies; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Kidney Glomerulus; Kidney Tubules; Lipids; Male; MAP Kinase Signaling System; Osteopontin; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats | 2014 |
Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta.
Topics: Aging; Animals; Aorta, Thoracic; Atorvastatin; Body Weight; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Rats, Wistar; Sirtuin 1 | 2014 |
Biological exposure indices of pyrrole adducts in serum and urine for hazard assessment of n-hexane exposure.
Topics: Adult; Animals; Biomarkers; Body Weight; Female; Gait; Hexanes; Humans; Male; Middle Aged; Occupational Exposure; Paralysis; Presynaptic Terminals; Pyrroles; Rats; Time Factors; Young Adult | 2014 |
Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Male; Pyrroles; Rats; Rats, Wistar; Triglycerides | 2014 |
Comparison of the effects of escitalopram and atorvastatin on diet-induced atherosclerosis in rats.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Body Weight; Citalopram; Diet, High-Fat; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Vascular Cell Adhesion Molecule-1 | 2014 |
Prevention of arterial stiffening by using low-dose atorvastatin in diabetes is associated with decreased malondialdehyde.
Topics: Animals; Arginine; Atorvastatin; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fatty Acids; Glycation End Products, Advanced; Hemodynamics; Heptanoic Acids; Lysine; Male; Malondialdehyde; Organ Size; Pyrroles; Rats, Wistar; Streptozocin; Vascular Stiffness | 2014 |
Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Berberine; Body Weight; Cells, Cultured; Cholesterol; Diet, High-Fat; Dietary Fats; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation; Heptanoic Acids; Macrophages; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Small Interfering; Scavenger Receptors, Class E; Signal Transduction; Triglycerides | 2014 |
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.
Topics: Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Indoles; Metabolic Clearance Rate; Models, Biological; Pyrroles; Sunitinib | 2015 |
Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia.
Topics: Animals; Antioxidants; Atorvastatin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet, Atherogenic; Heptanoic Acids; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Male; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrroles; Rats; Reactive Oxygen Species; Retina; Ubiquitin | 2014 |
Prevention of palatable diet-induced hyperphagia in rats by central injection of a VEGFR kinase inhibitor.
Topics: Analysis of Variance; Animals; Avoidance Learning; Body Weight; Diet; Drosophila; Eating; Enzyme Inhibitors; Feeding Behavior; Food Preferences; Hyperphagia; Indoles; Injections, Intraventricular; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Taste; Time Factors | 2015 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; Cyclooxygenase 2 Inhibitors; Enzyme Inhibitors; Female; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Precancerous Conditions; Pyrroles; Smoking; Survival Rate; Toxicity Tests, Subchronic | 2015 |
Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis.
Topics: Animals; Body Weight; CA1 Region, Hippocampal; Male; Pyrroles; Quinazolines; Rats; Rats, Wistar; Receptor, PAR-1; Status Epilepticus; Thrombin | 2015 |
Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.
Topics: Animals; Body Weight; Caco-2 Cells; Cytokines; Diet, High-Fat; Disease Models, Animal; Genetic Predisposition to Disease; Glucose Tolerance Test; Humans; Immunity, Innate; Inflammation; Insulin; Janus Kinase 3; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Obesity; Organ Size; Piperidines; Pyrimidines; Pyrroles; Risk Factors; Signal Transduction; Toll-Like Receptors | 2015 |
Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Azetidines; Body Weight; Caco-2 Cells; Cholesterol; Cholesterol, LDL; Cricetinae; Drug Evaluation, Preclinical; Fatty Acids; HEK293 Cells; Humans; Nitric Oxide; Pyrroles; Sulfanilamide; Sulfanilamides; Triglycerides | 2016 |
The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Avoidance Learning; Body Temperature; Body Weight; Cognition Disorders; Disease Models, Animal; Female; Indoles; Locomotion; Maze Learning; Mice; Nerve Degeneration; Prepulse Inhibition; Pyrroles; RNA, Messenger; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
Topics: Aminoquinolines; Animals; Antimalarials; Body Weight; Cell Line; Chloroquine; Humans; Malaria; Mice; Microsomes; Models, Chemical; Plasmodium berghei; Plasmodium falciparum; Pyrroles | 2008 |
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Topics: Acetylcholine; Animals; Atorvastatin; Blotting, Western; Body Weight; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; Drug Combinations; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocardium; Nitric Oxide Synthase Type III; Pulmonary Artery; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfonamides; Survival Analysis; Vasodilator Agents | 2008 |
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia
Topics: Animals; Benzodiazepines; Body Weight; Hyperphagia; Metabolic Diseases; Mice; Olanzapine; Piperazines; Pyrroles; Thiazepines; Weight Gain | 2008 |
The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-beta abundance.
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Weight; Cholesterol; Cholesterol, Dietary; Enterocytes; Ezetimibe; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intestinal Absorption; Mice; Mice, Inbred C57BL; Pyrroles; Random Allocation; Triglycerides | 2009 |
Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats.
Topics: Absorptiometry, Photon; Androgen Antagonists; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Estrogens; Female; Femur; Lumbar Vertebrae; Male; Orchiectomy; Organ Size; Osteocalcin; Ovariectomy; Pyrroles; Quinolones; Rats; Rats, Sprague-Dawley; Transcription, Genetic | 2009 |
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice.
Topics: Animals; Anti-Obesity Agents; Benzyl Compounds; Body Weight; Cannabinoids; Cerebellum; Chemistry, Pharmaceutical; Drug Design; Feeding Behavior; Humans; Inhibitory Concentration 50; Mice; Models, Chemical; Pyrroles; Rats; Receptors, Cannabinoid; Weight Gain | 2009 |
Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Atorvastatin; Blood Glucose; Body Weight; Brain; Dietary Fats; Female; Glutathione Peroxidase; Heptanoic Acids; Hyperglycemia; Hyperlipidemias; Insulin; Ketanserin; Lipid Peroxidation; Lipogenesis; Liver; Malondialdehyde; Mice; Mice, Inbred C57BL; Piperazines; PPAR gamma; Prazosin; Propranolol; Pyrroles; Superoxide Dismutase; Weight Gain | 2009 |
Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction.
Topics: Animals; Atorvastatin; Body Weight; Cardiac Volume; Collagen Type I; Collagen Type III; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2010 |
Social subordination and polymorphisms in the gene encoding the serotonin transporter enhance estradiol inhibition of luteinizing hormone secretion in female rhesus monkeys.
Topics: Analysis of Variance; Animals; Body Weight; Dominance-Subordination; Estradiol; Female; Hydrocortisone; Hypothalamo-Hypophyseal System; Individuality; Luteinizing Hormone; Macaca mulatta; Pituitary-Adrenal System; Polymorphism, Genetic; Pyrimidines; Pyrroles; Radioimmunoassay; Receptors, Corticotropin-Releasing Hormone; Serotonin Plasma Membrane Transport Proteins; Social Environment; Stress, Psychological | 2009 |
Effects of atorvastatin on the regeneration of pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent.
Topics: Animals; Animals, Newborn; Atorvastatin; Body Weight; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Male; Neovascularization, Physiologic; Organ Size; Pregnancy; Pyrroles; Rats; Rats, Wistar | 2010 |
Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Body Weight; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Indoles; Kidney; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Behavior, Animal; Body Weight; Corpus Striatum; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Nitrites; Oxidative Stress; Pyrroles; Quinolinic Acid; Rats; Rats, Wistar; Rotarod Performance Test; Simvastatin; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits.
Topics: Animals; Atorvastatin; Body Weight; Bronchoalveolar Lavage Fluid; Cell Proliferation; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Lung; Lung Diseases; Macrophages, Alveolar; Male; NF-kappa B; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrroles; Rabbits; Random Allocation | 2010 |
Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Body Weight; Brain; Cognition Disorders; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Maze Learning; Mice; Mice, Transgenic; Neuroprotective Agents; Organ Size; Phosphorylation; Plaque, Amyloid; Protein Processing, Post-Translational; Pyrroles; Quinolines; tau Proteins | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Avena; beta-Glucans; Blood; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fiber; Eating; Female; Heptanoic Acids; Intestinal Absorption; Lipids; Liver; Mice; Mice, Inbred Strains; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Treatment Outcome; Triglycerides | 2011 |
Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Body Weight; Caspase 3; Corpus Striatum; Dinoprostone; Huntington Disease; Interleukin-6; Lipid Peroxidation; Lipoxygenase; Male; Mitochondria; Motor Activity; Neuroprotective Agents; NF-kappa B; Nitrites; Nitro Compounds; Propionates; Prostaglandin-Endoperoxide Synthases; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Body Weight; Female; Humans; Immunoenzyme Techniques; Indoles; Lymphatic Metastasis; Lymphatic Vessels; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Tumor Cells, Cultured; Tyrosine; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.
Topics: Animals; Atorvastatin; Body Weight; Drug Interactions; Heart Failure; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Male; Myocardium; Organ Size; Pyrroles; Rats; Rats, Wistar; Ubiquinone; Ventricular Dysfunction, Left | 2011 |
Environmental enrichment has antidepressant-like action without improving learning and memory deficits in olfactory bulbectomized rats.
Topics: Analysis of Variance; Animals; Avoidance Learning; Body Weight; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Environment; Exercise Therapy; Exploratory Behavior; Indoles; Learning Disabilities; Locomotion; Maze Learning; Memory Disorders; Olfactory Bulb; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Recognition, Psychology; RNA, Messenger; Time Factors; Vascular Endothelial Growth Factor A | 2012 |
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Topics: Aged; Animals; Antineoplastic Agents; Body Weight; Capillaries; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Iodide Peroxidase; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Rats; Rats, Inbred WKY; Regional Blood Flow; Regression Analysis; Retrospective Studies; Stomach Neoplasms; Sunitinib; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2011 |
Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats.
Topics: Animals; Body Weight; Embryonic Development; Epididymis; Estrous Cycle; Female; Fertility; Indoles; Male; Organ Size; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Reproduction; Spermatozoa; Sunitinib; Testis; Toxicity Tests | 2012 |
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.
Topics: Animals; Body Weight; Imidazoles; Mice; Mice, Inbred C57BL; Nylons; Pyrroles | 2012 |
In vitro and in vivo toxicity of rinsed and aged nanocellulose-polypyrrole composites.
Topics: Animals; Body Weight; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Dermis; Electricity; Electrochemical Techniques; Fibroblasts; Humans; L-Lactate Dehydrogenase; Mice; Monocytes; Nanoparticles; Polymers; Pyrroles; Time Factors; Toxicity Tests; Toxicity Tests, Acute | 2012 |
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Topics: Animals; Antineoplastic Agents; Body Weight; Doxorubicin; Humans; Kinetics; Leukocytes; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Peptides; Pyrroles; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Somatostatin; Time Factors | 2005 |
Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Atorvastatin; Blood Pressure; Body Weight; Deoxyguanosine; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Infarction, Middle Cerebral Artery; Lipids; Lysine; Oxidative Stress; Pyrroles; Quinolines; Rats; Rats, Inbred SHR; Simvastatin; Survival Analysis | 2005 |
Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
Topics: Adipose Tissue; Animals; Atorvastatin; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phosphorylation; Pyrroles; Rats; Rats, Zucker | 2006 |
Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Cholesterol; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hypercholesterolemia; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha | 2005 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Chickens; Cholesterol; Down-Regulation; Female; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Liver; Organ Size; Point Mutation; Pyrroles; Receptors, LDL; RNA, Messenger; Triglycerides | 2006 |
Effect of atorvastatin treatment on isoproterenol-induced myocardial infarction in rats.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Body Weight; Catalase; Glutathione; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Lipid Peroxidation; Male; Myocardial Infarction; Myocardium; Necrosis; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2006 |
Atorvastatin prevented and partially reversed adrenocorticotropic hormone-induced hypertension in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Atorvastatin; Blood Pressure; Body Weight; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides | 2006 |
Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
Topics: Analysis of Variance; Animals; Atorvastatin; Biomarkers; Blood Pressure; Body Weight; Dexamethasone; Disease Models, Animal; Down-Regulation; Glucocorticoids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thymus Gland | 2006 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors | 2006 |
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
Topics: Animals; Anti-Obesity Agents; Body Weight; Crystallography, X-Ray; Drug Design; Eating; Humans; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Obesity; Piperidines; Pyrazoles; Pyridones; Pyrroles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Weight Gain | 2007 |
Effects of hypoxia on glucose, insulin, glucagon, and modulation by corticotropin-releasing factor receptor type 1 in the rat.
Topics: Altitude; Animals; Blood Glucose; Body Weight; Corticosterone; Eating; Glucagon; Hypoxia; Insulin; Leptin; Liver Glycogen; Male; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone | 2007 |
[Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Body Weight; Cardiovascular Diseases; Heptanoic Acids; Humans; Incidence; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Rural Health; Rural Population; Ukraine | 2006 |
Reversal of memory deficits by Atorvastatin and Simvastatin in rats.
Topics: Alprazolam; Amnesia; Animals; Atorvastatin; Body Weight; Cholesterol; Dietary Fats; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory; Pyrroles; Rats; Rats, Wistar; Reaction Time; Scopolamine; Simvastatin; Stimulation, Chemical | 2007 |
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
Topics: Adenosine; Administration, Oral; Animals; Atorvastatin; Body Weight; Cilostazol; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Immunoblotting; Male; Myocardium; Nitric Oxide Synthase Type III; Organ Culture Techniques; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Risk Factors; Tetrazoles; Treatment Outcome | 2007 |
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Topics: Animals; Atorvastatin; Biopterins; Body Weight; Cell Adhesion Molecules; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; GTP Cyclohydrolase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Oxidoreductases; Male; Microfilament Proteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Pyrroles; Rats; Rats, Wistar; Stem Cells; Tetrahydrofolate Dehydrogenase; Vasodilation | 2008 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Combined treatment with atorvastatin and minocycline suppresses severity of EAE.
Topics: Animals; Anti-Bacterial Agents; Atorvastatin; Body Weight; Cell Proliferation; Cytokines; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Female; Glial Fibrillary Acidic Protein; Glycoproteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Minocycline; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Neurologic Examination; Peptide Fragments; Pyrroles; Stereotaxic Techniques; T-Lymphocytes; Time Factors | 2008 |
Zomepirac-induced renal failure.
Topics: Acute Kidney Injury; Adult; Aged; Arthritis; Back Pain; Body Weight; Coronary Artery Bypass; Creatinine; Female; Headache; Humans; Male; Pain; Postoperative Complications; Pyrroles; Time Factors; Tolmetin | 1983 |
Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Dose-Response Relationship, Drug; Embryonic and Fetal Development; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pregnancy; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Toxicity Tests | 1994 |
Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Body Weight; Carrageenan; Cyclooxygenase Inhibitors; Edema; Female; Foot; Indomethacin; Male; Pyrroles; Rats; Rats, Wistar | 1995 |
ATP-sensitive K+ channel openers inhibit morphine withdrawal.
Topics: Adenosine Triphosphate; Animals; Behavior, Animal; Benzopyrans; Body Weight; Cromakalim; Diazoxide; Dose-Response Relationship, Drug; Female; Injections, Intraventricular; Injections, Subcutaneous; Mice; Mice, Inbred Strains; Morphine; Naloxone; Potassium Channels; Pyrroles; Substance Withdrawal Syndrome | 1994 |
Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats.
Topics: Animals; Benzopyrans; Blood Pressure; Body Weight; Cromakalim; Dose-Response Relationship, Drug; Glyburide; Hydralazine; Membrane Potentials; Mesenteric Arteries; Parasympatholytics; Patch-Clamp Techniques; Potassium Channels; Pulse; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Species Specificity | 1996 |
Hepatotoxicity of 1,3,5-trinitro-2-acetyl pyrrole derived from nitrosation of Maillard reaction product in BALB/C mouse.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cysts; Liver; Male; Mice; Mice, Inbred BALB C; Mortality; Pyrroles | 1996 |
Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
Topics: Animals; Antineoplastic Agents; Body Weight; Cytotoxins; Doxorubicin; Female; Gonadotropin-Releasing Hormone; Growth Hormone; Luteinizing Hormone; Menstrual Cycle; Pituitary Function Tests; Pituitary Gland, Anterior; Pyrroles; Rats; Rats, Sprague-Dawley; Thyrotropin | 1997 |
Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats.
Topics: Animals; Area Under Curve; Atorvastatin; Behavior, Animal; Body Weight; Eating; Female; Fertility; Gastric Mucosa; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactation; Male; Postural Balance; Pregnancy; Pregnancy, Animal; Prenatal Exposure Delayed Effects; Pyrroles; Rats; Rats, Sprague-Dawley; Reflex, Startle; Survival Rate; Tissue Distribution | 1998 |
Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation.
Topics: Adipose Tissue; Adrenal Glands; Adrenocorticotropic Hormone; Animals; Apoptosis; Blotting, Northern; Body Weight; Corticosterone; Leptin; Male; Metabolism; Microscopy, Electron; Pituitary Gland; Proteins; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; RNA, Messenger | 1998 |
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Topics: Animals; Antibiotics, Antineoplastic; Body Weight; Cell Survival; Doxorubicin; Glioblastoma; Humans; Male; Mice; Mice, Nude; Octreotide; Pyrroles; Transfection; Tumor Cells, Cultured | 2000 |
Effects of new antioxidant compounds PNU-104067F and PNU-74389G on antioxidant defense in normal and diabetic rats.
Topics: Animals; Antioxidants; Body Weight; Diabetes Mellitus, Experimental; Liver; Male; Organ Size; Pregnatrienes; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley | 2000 |
Inhibition of angiogenesis decreases alveolarization in the developing rat lung.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Barium Sulfate; Body Weight; Cyclohexanes; Fatty Acids, Unsaturated; Gelatin; Heart; Indoles; Injections, Intra-Arterial; Lung; Neovascularization, Physiologic; Organ Size; Pulmonary Alveoli; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sesquiterpenes; Thalidomide | 2000 |
Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice.
Topics: Animals; Body Weight; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Female; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Intestines; Mice; Mice, Inbred C57BL; Organ Size; Peptides; Pyrroles; Rats; Rats, Wistar; Recombinant Proteins; Valine | 2000 |
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin.
Topics: Administration, Oral; Animals; Animals, Newborn; Atorvastatin; Blood Pressure; Body Weight; DNA; Heart; Heart Rate; Heart Ventricles; Heptanoic Acids; Mitogen-Activated Protein Kinases; Myocardium; Organ Size; Pravastatin; Proteins; Pyrroles; RNA; Simvastatin; Swine; Water | 2001 |
Anti-inflammatory and antiplatelet effects of amtolmetin guacyl, a new gastroprotective non-steroidal anti-inflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Body Weight; Bone Density; Carrageenan; Dose-Response Relationship, Drug; Exudates and Transudates; Glycine; In Vitro Techniques; Indomethacin; Male; Piroxicam; Platelet Aggregation; Platelet Aggregation Inhibitors; Pleurisy; Pyrroles; Rats; Thromboxane B2 | 2001 |
Subacute toxicity of a halogenated pyrrole hydroxymethylglutaryl-coenzyme A reductase inhibitor in Wistar rats.
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Keratosis; Liver; Male; Mevalonic Acid; Necrosis; Neoplasms, Experimental; Organ Size; Pyrroles; Rats; Rats, Wistar; Stomach; Stomach Diseases | 1992 |
Effect of 2(3)-tert-butyl-4-hydroxyanisole (BHA) and 2-chloroethanol against pyrrole production and chronic toxicity of monocrotaline in chickens.
Topics: Animals; Body Weight; Butylated Hydroxyanisole; Chickens; Chlorohydrins; Ethylene Chlorohydrin; Female; Liver; Male; Monocrotaline; Organ Size; Pyrroles; Pyrrolizidine Alkaloids | 1987 |
Comparative neurotoxicity and pyrrole-forming potential of 2,5-hexanedione and perdeuterio-2,5-hexanedione in the rat.
Topics: Animals; Ataxia; Axons; Body Weight; Cytoskeletal Proteins; Deuterium; Hexanones; Injections, Intraperitoneal; Ketones; Male; Pyrroles; Rats; Rats, Inbred Strains; Spinal Cord | 1988 |
The rate of 2,5-hexanedione intoxication, not total dose, determines the extent of testicular injury and altered microtubule assembly in the rat.
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Hexanones; Ketones; Male; Microtubules; Organ Size; Pyrroles; Rats; Testis; Time Factors | 1988 |
Structural basis of gamma-diketone neurotoxicity: non-neurotoxicity of 3,3-dimethyl-2,5-hexanedione, a gamma-diketone incapable of pyrrole formation.
Topics: Animals; Axons; Body Weight; Hexanones; Intermediate Filaments; Male; Nervous System; Pyrroles; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1986 |
Comparative efficacy of one and two treatments with tubercidin against Schistosomiasis japonica in monkeys.
Topics: Animals; Anthelmintics; Body Weight; Colon; Feces; Female; Granuloma; Haplorhini; Liver; Liver Diseases, Parasitic; Macaca; Male; Mollusca; Pyrimidines; Pyrroles; Ribonucleosides; Schistosoma; Schistosomiasis | 1974 |
Antimitotic effects of dehydroretronecine pyrrole.
Topics: Animals; Blood Proteins; Body Weight; Diarrhea; Gastric Mucosa; Gastrointestinal Hemorrhage; Hemoglobins; Leukocyte Count; Male; Methanol; Mitosis; Pyrroles; Pyrrolizidine Alkaloids; Rats; Remission, Spontaneous; Serum Albumin; Serum Globulins; Spleen; Stomach Ulcer; Thymus Gland | 1974 |
Pulmonary oedema in rats given monocrotaline pyrrole.
Topics: Alkaloids; Animals; Body Weight; Chromium Isotopes; Female; Hematocrit; Heterocyclic Compounds; Injections, Intravenous; Iodine Isotopes; Lung; Male; Microscopy, Electron; Organ Size; Pleural Effusion; Pulmonary Edema; Pyrroles; Rats; Time Factors | 1972 |
[Anti-inflammatory effect of bimetopyrol. II. Suppressive effect on adjuvant arthritis in rats].
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Body Weight; Female; Flufenamic Acid; Glucocorticoids; Indomethacin; Organ Size; Phenylbutazone; Pyrroles; Rats; Rats, Inbred Strains | 1972 |
Effect of glycine loading on Delta-Aminolevulinic acid (ALA) and porphobilinogen (PBG) excretion during starvation.
Topics: Adolescent; Adult; Amino Acids; Body Weight; Female; Glycine; Humans; Hydro-Lyases; Levulinic Acids; Male; Middle Aged; Obesity; Porphyrias; Porphyrins; Propionates; Pyrroles; Starvation | 1969 |
Immune response and pyrrole levels in rat sera after a single injection of methionine sulphoximine as compared with the effect of whole body irradiation with x-rays.
Topics: Animals; Body Weight; Hemolysis; Hypothalamus; Immune Tolerance; Injections, Intraperitoneal; Male; Methionine; Methionine Sulfoximine; Paramecium; Pyrroles; Radiation Effects; Rats; Serum Albumin; Serum Globulins; Time Factors | 1969 |